[ Contents | Search | Post | Reply | Next | Previous | Up ]
From: Ryan Pollard
Date: 13 Oct 2008
Time: 12:14:13 -0500
Remote Name: 128.138.64.103
Regarding your first question: no, I think I’m ready to move on with my research and explore other areas of stuttering. Our qualified conclusion from our study was that larger, Phase II trials are not warranted for the SpeachEasy, but the device helped some subjects in certain ways and therefore does have some clinical worth. As for replacing a client’s hopes for a panacea with more realistic expectations, the clinician must be on top of this from the moment of first contact with the client. Media portrayals of any type of remedy can powerfully affect consumers’ views and the clinician may have to temper unrealistic outlooks. A good way to help set appropriate expectations is to be knowledgeable of current research on the device and able to relay those results to the client as simply as possible. Also, it’s important to remind the client that for many SpeechEasy users, some degree of active, ongoing stuttering management on the part of the user will be needed to produce the best results.